MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights.

Multiple sclerosis (MS) is a chronic disease and one of the leading causes of disability in young adults. The current study aims to investigate the pathogenesis of MS via studying the regulatory role of novel lncRNA MAGI2-AS3 in miR-374b-5p and their downstream targets PTEN/AKT/IRF-3/IFN-β and the relationship of this pathway with disease severity. Moreover, it aims to assess the role of MAGI2-AS3/miR-374b-5p as diagnostic and/or prognostic biomarkers for MS. Overall, 150 contributors were recruited: 100 patients with MS and 50 healthy volunteers. Gene expression of MAGI2-AS3, miR-374b-5p, PTEN, AKT, and IRF-3 were assessed using RT-qPCR, and IFN-β was measured by ELISA. Compared with the healthy control group, serum MAGI2-AS3 and PTEN were downregulated in MS patients, whereas miR-374b-5p, PI3K, AKT, IRF-3, and IFN-β were upregulated in MS patients. Furthermore, MAGI2-AS3 was downregulated, while miR-374b-5p was upregulated in MS patients with an expanded disability status scale (EDSS) ≥3.5, compared to patients with an EDSS <3.5. Receiver-operating-characteristic curve analysis revealed that MAGI2-AS3 and miR-374b-5p can be used in the diagnosis of MS. Remarkably, multivariate logistic analysis revealed that MAGI2-AS3, miR-374b-5p, PTEN, and AKT act as independent variables in MS. Moreover, MAGI2-AS3 was directly correlated with PTEN and inversely correlated with miR-374b-5p, AKT, and EDSS. Regarding miR-374b-5p, it was positively correlated with AKT and EDSS. In conclusion, the study showed for the first time that the crosstalk between MAGI2-AS3 and miR-374b-5p could affect the AKT/IRF3/IFN-β axis in MS. Interestingly, MAGI2-AS3 and miR-374b-5p could be genetic noninvasive biomarkers for MS.

[1]  Kawkab A. Ahmed,et al.  The neuroprotective effect of pterostilbene on oxaliplatin-induced peripheral neuropathy via its anti-inflammatory, anti-oxidative and anti-apoptotic effects: Comparative study with celecoxib. , 2023, Life sciences.

[2]  Mai A. Abd-Elmawla,et al.  LncRNA MEG3 regulates the interplay between Th17 and Treg cells in Behçet's disease and systemic lupus erythematosus. , 2022, Life sciences.

[3]  M. Rogić Vidaković,et al.  Psychometric Properties of the Pittsburgh Sleep Quality Index (PSQI) in Patients with Multiple Sclerosis: Factor Structure, Reliability, Correlates, and Discrimination , 2022, Journal of clinical medicine.

[4]  M. Ashrafizadeh,et al.  Gene regulation by antisense transcription: A focus on neurological and cancer diseases. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  Yibing Chen,et al.  lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment , 2021, Molecular therapy. Nucleic acids.

[6]  O. Shaker,et al.  Genetic and epigenetic control on clock genes in multiple sclerosis. , 2021, Journal of genetics and genomics = Yi chuan xue bao.

[7]  S. Ozen,et al.  Inflammation-related differentially expressed common miRNAs in systemic autoinflammatory disorders patients can regulate the clinical course. , 2021, Clinical and experimental rheumatology.

[8]  O. Shaker,et al.  Association of MALAT1 and PVT1 Variants, Expression Profiles and Target miRNA-101 and miRNA-186 with Colorectal Cancer: Correlation with Epithelial-Mesenchymal Transition , 2021, International journal of molecular sciences.

[9]  Fei Liu,et al.  lncRNA MAGI2‐AS3 overexpression had antitumor effect on Hepatic cancer via miRNA‐23a‐3p/PTEN axis , 2021, Food science & nutrition.

[10]  Jingjing Zhang,et al.  Deregulated lncRNA MAGI2-AS3 in Alzheimer's disease attenuates amyloid-β induced neurotoxicity and neuroinflammation by sponging miR-374b-5p , 2020, Experimental Gerontology.

[11]  Songhao Yang,et al.  MiR-374b-5p Regulates T Cell Differentiation and Is Associated with rEg.P29 Immunity , 2020, BioMed research international.

[12]  F. Jadidi-Niaragh,et al.  The emerging role of lncRNAs in multiple sclerosis , 2020, Journal of Neuroimmunology.

[13]  S. Al‐Mayouf,et al.  Systemic lupus erythematosus in a girl with PTEN variant and transaldolase deficiency: a novel phenotype , 2020, Clinical Rheumatology.

[14]  Ran Wei,et al.  miR-374b-5p is increased in deep vein thrombosis and negatively targets IL-10. , 2020, Journal of molecular and cellular cardiology.

[15]  O. Shaker,et al.  LncRNA GAS5 and miR-137 polymorphisms and expression are associated with multiple sclerosis risk: mechanistic insights and potential clinical impact. , 2020, ACS chemical neuroscience.

[16]  M. Taheri,et al.  A comprehensive review of non-coding RNAs functions in multiple sclerosis. , 2020, European journal of pharmacology.

[17]  Lixin Na,et al.  Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours , 2020, Cell & Bioscience.

[18]  M. Zannini,et al.  Long Non-Coding RNA MAGI2-AS3 is a New Player with a Tumor Suppressive Role in High Grade Serous Ovarian Carcinoma , 2019, Cancers.

[19]  Sunit K. Singh,et al.  Modulation of Type-I Interferon Response by hsa-miR-374b-5p During Japanese Encephalitis Virus Infection in Human Microglial Cells , 2019, Front. Cell. Infect. Microbiol..

[20]  M. Jagodic,et al.  Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview. , 2019, Journal of autoimmunity.

[21]  Chuanzhao Zhang,et al.  LncRNA MAGI2‐AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR‐374b‐5p/SMG1 signaling pathway , 2019, Journal of cellular physiology.

[22]  Hongjun Bian,et al.  The latest progress on miR‐374 and its functional implications in physiological and pathological processes , 2019, Journal of cellular and molecular medicine.

[23]  H. Lassmann.  Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis , 2019, Front. Immunol..

[24]  G. Giovannoni,et al.  Multiple sclerosis – a review , 2018, European journal of neurology.

[25]  Sherine M Rizk,et al.  Role of long non-coding RNAs expression (ANRIL, NOS3-AS, and APOA1-AS) in development of atherosclerosis in Egyptian systemic lupus erythematosus patients , 2018, Clinical Rheumatology.

[26]  H. Zéphir.  Progress in understanding the pathophysiology of multiple sclerosis. , 2018, Revue neurologique.

[27]  Hyeon-Beom Seo,et al.  PTEN ameliorates autoimmune arthritis through down-regulating STAT3 activation with reciprocal balance of Th17 and Tregs , 2016, Scientific Reports.

[28]  Yuxin Yin,et al.  The tumor suppressor PTEN has a critical role in antiviral innate immunity , 2015, Nature Immunology.

[29]  D. Goodin,et al.  A comparative analysis of Patient-Reported Expanded Disability Status Scale tools , 2015, Multiple sclerosis.

[30]  G. Superti-Furga,et al.  Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis , 2015, Arthritis Research & Therapy.

[31]  Shung-Haur Yang,et al.  A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancer , 2015, World Journal of Surgical Oncology.

[32]  Xin Zhang,et al.  The role of TLR4-mediated PTEN/PI3K/AKT/NF-κB signaling pathway in neuroinflammation in hippocampal neurons , 2014, Neuroscience.

[33]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.